ITC Initiates Clinical Trials Of Its Nasal Spray For COVID-19 Prevention: Report
ITC Limited (ITC official website)

Diversified entity ITC on Thursday confirmed that it is developing a nasal spray for COVID-19 prevention for which it has initiated clinical trials.

Developed by scientists at ITC Life Sciences and Technology Centre (LSTC), Bengaluru, the company plans to market the nasal spray under the Savlon brand once it gets all the requisite regulatory approvals, according to sources.

When contacted for comments, a spokesperson of ITC said, "We are unable to share more details at the current moment as the clinical trials are underway."

The spokesperson declined to comment on a detailed query on where is the clinical trial being done, from where the commercial production would be done when approved and under what brand the nasal spray would be marketed.

However, sources said the company had received approvals from ethics committees and is registered with Clinical Trial Registry-India (CTRI) for clinical trials of the nasal spray which is designed to arrest the virus at the entry point in the nasal cavity itself.

They further said the product has the potential to be effective and safe in preventing infection and transmission of COVID-19 along with the existing measures of hygiene recommended by health authorities.

ITC's LSTC has been at the core of the company's drive for science led product innovation to support and build its wide range of product portfolio.

The company's R&D teams were instrumental in developing a range of innovative health and hygiene offerings that were commercially made available under the Savlon brand, during the pandemic.

This news has been published via a Syndicated feed. Only the headline is changed.

Tags: 

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber
Advertisement